NEW DELHI -
July 28, 2025 -
PRLog -- The global multiple myeloma therapeutics market was valued at USD 27,013 Million in 2024, and is projected to reach USD 39,084 Million by 2030, driven by the rising prevalence of multiple myeloma, improved diagnostic criteria, an aging population, and increasing adoption of targeted treatments. Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to organ dysfunction and, eventually, death. The treatment for multiple myeloma includes a variety of interventions, such as chemotherapy, targeted therapy, immunomodulatory agents, radiation therapy, and stem cell transplantation. These therapies aim to manage the disease, prolong remission, and improve overall survival and quality of life for patients. The increasing awareness of multiple myeloma leads to more individuals being diagnosed with the disease, creating significant global demand for effective treatment options. For instance, according to the National Cancer Institute, approximately 36,110 new cases of multiple myeloma are expected to be diagnosed in the U.S. in 2025, reflecting a steady rise in incidence rates. Early diagnosis and tailored treatment approaches are crucial for enhancing patient outcomes and increasing survival rates, which in turn drive market expansion.
For more details, please visit:
https://apeloconsulting.com/product/global-multiple-myelo...
Account Phone Number